» Articles » PMID: 26342240

Statistical Identifiability and Sample Size Calculations for Serial Seroepidemiology

Overview
Journal Epidemics
Publisher Elsevier
Date 2015 Sep 7
PMID 26342240
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Inference on disease dynamics is typically performed using case reporting time series of symptomatic disease. The inferred dynamics will vary depending on the reporting patterns and surveillance system for the disease in question, and the inference will miss mild or underreported epidemics. To eliminate the variation introduced by differing reporting patterns and to capture asymptomatic or subclinical infection, inferential methods can be applied to serological data sets instead of case reporting data. To reconstruct complete disease dynamics, one would need to collect a serological time series. In the statistical analysis presented here, we consider a particular kind of serological time series with repeated, periodic collections of population-representative serum. We refer to this study design as a serial seroepidemiology (SSE) design, and we base the analysis on our epidemiological knowledge of influenza. We consider a study duration of three to four years, during which a single antigenic type of influenza would be circulating, and we evaluate our ability to reconstruct disease dynamics based on serological data alone. We show that the processes of reinfection, antibody generation, and antibody waning confound each other and are not always statistically identifiable, especially when dynamics resemble a non-oscillating endemic equilibrium behavior. We introduce some constraints to partially resolve this confounding, and we show that transmission rates and basic reproduction numbers can be accurately estimated in SSE study designs. Seasonal forcing is more difficult to identify as serology-based studies only detect oscillations in antibody titers of recovered individuals, and these oscillations are typically weaker than those observed for infected individuals. To accurately estimate the magnitude and timing of seasonal forcing, serum samples should be collected every two months and 200 or more samples should be included in each collection; this sample size estimate is sensitive to the antibody waning rate and the assumed level of seasonal forcing.

Citing Articles

serosim: An R package for simulating serological data arising from vaccination, epidemiological and antibody kinetics processes.

Menezes A, Takahashi S, Routledge I, Metcalf C, Graham A, Hay J PLoS Comput Biol. 2023; 19(8):e1011384.

PMID: 37578985 PMC: 10449138. DOI: 10.1371/journal.pcbi.1011384.


Prevalence and predictors of anti-SARS-CoV-2 serology in a highly vulnerable population of Rio de Janeiro: A population-based serosurvey.

Coelho L, Luz P, Pires D, Jalil E, Perazzo H, Torres T Lancet Reg Health Am. 2022; 15:100338.

PMID: 35936224 PMC: 9337985. DOI: 10.1016/j.lana.2022.100338.


Effects of Accounting for Interval-Censored Antibody Titer Decay on Seroincidence in a Longitudinal Cohort Study of Leptospirosis.

Owers Bonner K, Cruz J, Sacramento G, de Oliveira D, Nery N, Carvalho M Am J Epidemiol. 2020; 190(5):893-899.

PMID: 33274738 PMC: 8096484. DOI: 10.1093/aje/kwaa253.


Linking longitudinal and cross-sectional biomarker data to understand host-pathogen dynamics: Leptospira in California sea lions (Zalophus californianus) as a case study.

Prager K, Buhnerkempe M, Greig D, Orr A, Jensen E, Gomez F PLoS Negl Trop Dis. 2020; 14(6):e0008407.

PMID: 32598393 PMC: 7351238. DOI: 10.1371/journal.pntd.0008407.


Sample size calculation for estimating key epidemiological parameters using serological data and mathematical modelling.

Blaizot S, Herzog S, Abrams S, Theeten H, Litzroth A, Hens N BMC Med Res Methodol. 2019; 19(1):51.

PMID: 30845904 PMC: 6407263. DOI: 10.1186/s12874-019-0692-1.


References
1.
Grilli E, Davies J, Smith A . Infection with influenza A H1N1. 1. Production and persistence of antibody. J Hyg (Lond). 1986; 96(2):335-43. PMC: 2129637. DOI: 10.1017/s0022172400066080. View

2.
Vongphrachanh P, Simmerman J, Phonekeo D, Pansayavong V, Sisouk T, Ongkhamme S . An early report from newly established laboratory-based influenza surveillance in Lao PDR. Influenza Other Respir Viruses. 2010; 4(2):47-52. PMC: 5779283. DOI: 10.1111/j.1750-2659.2009.00120.x. View

3.
McLeish N, Simmonds P, Robertson C, Handel I, McGilchrist M, Singh B . Sero-prevalence and incidence of A/H1N1 2009 influenza infection in Scotland in winter 2009-2010. PLoS One. 2011; 6(6):e20358. PMC: 3110753. DOI: 10.1371/journal.pone.0020358. View

4.
Iwatsuki-Horimoto K, Horimoto T, Tamura D, Kiso M, Kawakami E, Hatakeyama S . Seroprevalence of pandemic 2009 (H1N1) influenza A virus among schoolchildren and their parents in Tokyo, Japan. Clin Vaccine Immunol. 2011; 18(5):860-6. PMC: 3122524. DOI: 10.1128/CVI.00428-10. View

5.
Todd S, de Bruin E, Nhat N, Koopmans M, Boni M . Reply to Pawar et al. J Infect Dis. 2014; 210(1):161-3. PMC: 4054897. DOI: 10.1093/infdis/jiu034. View